The Coronavirus Aid, Relief, and Economic Security (CARES) Act encourages charitable giving by increasing tax incentives for individuals and corporations. We want to make sure that anyone who supports us […]
In October 2020, Santhera Pharmaceuticals announced the disappointing news that it was discontinuing its Phase 3 SIDEROS trial of Puldysa (idebenone) in Duchenne muscular dystrophy. The data from a pre-planned […]
Santhera discusses the SIDEROS interim analysis, presents results and answers questions from the community in this CureDuchenne Webinar: SIDEROS Interim Analysis – Outcomes and Key Learnings. You’ll be prompted to […]
CureDuchenne is pleased to share the news that Edgewise Therapeutics is starting a Phase 1 clinical trial to assess the safety, tolerability, and appropriate dose of their experimental therapeutic aimed […]
– EDG-5506 is a novel, oral, small molecule drug candidate with the potential to promote muscle function in patients with muscular dystrophy – Boulder, Colo., (November 11, 2020) – Edgewise […]
CureDuchenne Ventures is happy to announce an investment in Mesentech, a company based in Vancouver, Canada, that has a novel therapeutic approach for improving bone density and strength. This investment […]
CURE DUCHENNE VENTURES INVESTMENT SUPPORTS THE DEVELOPMENT OF A NEW THERAPY FOR BONE WASTAGE IN DUCHENNE MUSCULAR DYSTROPHY Newport Beach, CA (November 10, 2020) – CureDuchenne Ventures, the research funding […]
November 9, 2020 Results from all cohorts of PRECISION-HD1 and PRECISION-HD2 clinical trials and initial OLE data on track for 1Q 2021Dosing in three new clinical trials with novel compounds […]
11/05/20 4:02 PM EST — Dosing with SRP-9001 commercial-process material to proceed following discussions with U.S. FDA — — Clinical dosing is expected to begin before the end of 2020 — CAMBRIDGE, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in […]
